• If you are wondering whether Rhythm Pharmaceuticals at US$96.61 is still a sensible entry or addition to your portfolio after a strong run, this article focuses squarely on what the current price may or may not reflect about value.
• The stock has moved sharply in the short term, with a 17.6% return over the last week and 11.1% over the last month. Year to date it is down 8.0% and the 1 year return sits at 49.5%.
• Over the last three years the stock return is very large, and over five years it is also very large, which naturally raises questions about what is already priced in. Recent coverage has highlighted Rhythm Pharmaceuticals as a fast moving biotech, which helps explain why investors are closely watching each new development and reassessing risk and reward.
• Simply Wall St currently gives Rhythm Pharmaceuticals a value score of 3 out of 6. The rest of this article will break down what that means across different valuation methods and point you toward an even more useful way to think about valuation at the end.

Approach 1: Rhythm Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and then discounting them back to today using a required rate of return. It focuses on the cash the business might generate for shareholders rather than short term earnings.

For Rhythm Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of $159.9 million. Analyst and extrapolated projections move from a projected free cash flow of $242 million in 2026 and $84.3 million in 2027, to positive figures of $257.5 million in 2028, $401 million in 2029 and $734.3 million in 2030, all in $.

When all projected cash flows out to 2035 are discounted back, Simply Wall St arrives at an estimated intrinsic value of about $506.69 per share. Compared with the current share price of $96.61, this DCF output suggests Rhythm Pharmaceuticals stock is 80.9% undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Rhythm Pharmaceuticals is undervalued by 80.9%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: Rhythm Pharmaceuticals Price vs Sales

For companies where earnings are not yet the main focus, price to sales (P/S) is often a useful cross check because it compares the value the market places on the stock with the revenue it generates.

In general, higher growth expectations and lower perceived risk can support a higher P/S ratio, while slower expected growth or higher uncertainty can lead investors to pay a lower multiple for each dollar of sales.

Rhythm Pharmaceuticals currently trades on a P/S ratio of 30.49x. This sits well above the Biotechs industry average P/S of 10.93x and above the peer average of 8.68x, so on simple comparisons the stock carries a much higher sales multiple than many peers.

Simply Wall St also provides a proprietary Fair Ratio of 17.03x for Rhythm Pharmaceuticals. This is an estimated P/S multiple that reflects factors such as earnings growth, industry, profit margin, market cap and risk profile.

Because the Fair Ratio incorporates these company specific drivers, it can be more informative than a basic comparison with peer and industry averages, which treat all companies as if they face the same opportunities and risks.

Comparing the Fair Ratio of 17.03x with the current P/S of 30.49x suggests the stock is trading above what the model views as a fair level.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Rhythm Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced. These are simple stories you create about Rhythm Pharmaceuticals that tie your view on its products, risks and opportunities to specific forecasts for revenue, earnings and margins. This produces a fair value you can compare with the current price on Simply Wall St's Community page, where different Narratives, such as a more optimistic view using the US$158 price target and a more cautious view using the US$105 price target, sit side by side and automatically refresh when new earnings, news or regulatory updates arrive. This can help you decide whether the gap between your Fair Value and the live share price looks wide enough to act on or too tight to justify a trade.

Do you think there's more to the story for Rhythm Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.